Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OliX Eyes RNAi Leadership In Asia And Beyond

Executive Summary

Emerging Company Profile: Alnylam's success with late-stage patisiran raised expectations for other RNAi firms, like South Korea's OliX Pharmaceuticals. OliX is developing locally administered treatments for dermal, ophthalmic and pulmonary indications in hopes of cementing its leadership in Asia and beyond.

Advertisement

Related Content

Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018
APOLLO Success Clears Alnylam For Lift-Off
OPKO terminates Phase III trial of macular degeneration candidate

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel